Working… Menu

Advanced Reperfusion Strategies for Refractory Cardiac Arrest (ARREST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03880565
Recruitment Status : Active, not recruiting
First Posted : March 19, 2019
Last Update Posted : August 13, 2020
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:
This is a Phase II, single center (Under the Center for Resuscitation Medicine at the University of Minnesota Medical School), partially blinded, prospective, intention to treat, safety and efficacy clinical trial, randomizing adult patients (18-75 years old) with refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/VT) out-of hospital cardiac arrest (OHCA) who are transferred by emergency medical services (EMS) with ongoing mechanical cardiopulmonary resuscitation (CPR) or who are resuscitated to receive one of the 2 local standards of care practiced in our community: 1) Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation or 2) Standard Advanced Cardiac Life Support (ACLS) Resuscitation

Condition or disease Intervention/treatment Phase
Cardiac Arrest Extracorporeal Membrane Oxygenation Complication Ventricular Fibrillation Pulseless Ventricular Tachycardia Out-Of-Hospital Cardiac Arrest Device: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation Device: Standard Advanced Cardiac Life Support (ACLS) Resuscitation Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Advanced REperfusion STrategies for Refractory Cardiac Arrest (The ARREST Trial)
Actual Study Start Date : August 9, 2019
Actual Primary Completion Date : June 9, 2020
Estimated Study Completion Date : January 5, 2021

Arm Intervention/treatment
Experimental: ECMO Facilitated Resuscitation
Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation: ECMO is initiated expeditiously, regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
Device: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation
Early use of ECMO

Standard ACLS Resuscitation
Standard Advanced Cardiac Life Support (ACLS) Resuscitation: Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
Device: Standard Advanced Cardiac Life Support (ACLS) Resuscitation
Standard life support resuscitation

Primary Outcome Measures :
  1. Survival [ Time Frame: 1 week ]
    Survival to hospital discharge.

Secondary Outcome Measures :
  1. Survival to hospital discharge with modified Rankin Scale Score (mRS) ≤ 3 along with functional status (Cerebral Performance Category [CPC]) [ Time Frame: 1 week, 3 months, 6 months ]
    Survival to hospital discharge with mRS ≤ 3 along with functional status as measured by CPC. mRS scale ranges from 0 (no residual symptoms) to 6 (dead) with 7 (unable to contact patient/caregiver) and 8 (mRS not performed). Scores of 3 (the patient has moderate disability), 2 (the patient has slight disability), 1 (the patient has no significant disability), and 0 indicate favorable outcome. CPC scale ranges from 1 (good cerebral performance) to 5 (brain death). CPC scores of 2 (moderate cerebral disability) and 1 indicate functional status.

  2. Treatment cost [ Time Frame: 6 months ]
    Cost per patient and cost per life saved

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (presumed or known to be aged 18-75 years, inclusive),
  • An initial documented OHCA rhythm of VF/VT,
  • No ROSC following 3 defibrillation shocks,
  • Body morphology able to accommodate a Lund University Cardiac Arrest System (LUCAS™) automated CPR device, and
  • Estimated transfer time from the scene to the ED or CCL of < 30 minutes.

Exclusion Criteria:

  • Age < 18 years old or > 75 years old;
  • Non-shockable initial OHCA rhythm (pulseless electrical activity [PEA] or asystole);
  • Valid do-not-attempt-resuscitation orders (DNAR);
  • Blunt, penetrating, or burn-related injury, drowning, electrocution or known overdose;
  • Known prisoners;
  • Known pregnancy;
  • Nursing home residents;
  • Unavailability of the cardiac catheterization laboratory.
  • Severe concomitant illness that drastically shortens life expectancy or increases risk of the procedure;
  • Absolute contraindications to emergent coronary angiography including known anaphylactic reaction to angiographic contrast media and/or active gastrointestinal or internal bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03880565

Layout table for location information
United States, Minnesota
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota
Layout table for investigator information
Principal Investigator: Demetris Yannopoulos, MD University of Minnesota
Study Chair: Tom Aufderheide, MD University of Minnesota
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Minnesota Identifier: NCT03880565    
Other Study ID Numbers: CV-2018-27226
First Posted: March 19, 2019    Key Record Dates
Last Update Posted: August 13, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by University of Minnesota:
advanced reperfusion
mechanical cardiopulmonary resuscitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Tachycardia, Ventricular
Out-of-Hospital Cardiac Arrest
Ventricular Fibrillation
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Cardiac Conduction System Disease
Pathologic Processes